Yazeid Alshebani
Cardiovascular Disease · Indianapolis, INNPI 1124422936
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.5%), travel and lodging and education — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by Medtronic at 58.2% of the total. Reporting peaked in 2019 at $990 and has fallen 85.1% since, to $148 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in IN, where the typical reported total is $2,452.
Across 53 payments — averaging $31.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$962
- Amgen$108
- Pfizer$85
- Chiesi USA, Inc.$82
- AstraZeneca$69
- Merck$57
- plus $291 from 13 others
What the payments were for
- Travel & lodging$80649%
- Food & beverage$83651%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 9 | $962 |
| Amgen | 7 | $108 |
| Pfizer | 5 | $85 |
| Chiesi USA, Inc. | 5 | $82 |
| AstraZeneca | 3 | $69 |
| Merck | 4 | $57 |
| Boehringer Ingelheim | 3 | $44 |
| Esperion Therapeutics, Inc. | 2 | $35 |
| Johnson & Johnson | 2 | $29 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $26 |
| Eagle Pharmaceuticals, Inc. | 1 | $25 |
| Novartis | 2 | $25 |
| Novo Nordisk | 1 | $22 |
| Actelion Pharmaceuticals US, Inc. | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $15 |
| Penumbra, Inc. | 1 | $13 |
| Cvrx, Inc. | 1 | $6 |
How this compares
$1,654 in reported general payments places this provider in the 40th percentile of 408 cardiovascular disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 17 | $279 |
| Rosuvastatin Calcium | 33 | $266 |
| Furosemide | 37 | $148 |
| Losartan Potassium | 19 | $143 |
| Atorvastatin Calcium | 14 | $132 |
| Carvedilol | 12 | $95 |
| Amlodipine Besylate | 20 | $71 |
| Metoprolol Tartrate | 19 | $12 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Indianapolis
- John MillerIndianapolis$354K
- David KovacichIndianapolis$327K
- Vijay RaoIndianapolis$247K
- Atul ChughIndianapolis$242K
- James TrippiIndianapolis$239K
- Christopher HealyIndianapolis$209K
- Richard KovacsIndianapolis$136K
- George LolayIndianapolis$128K
- Onyedika IlonzeIndianapolis$125K
- Noel DasguptaIndianapolis$122K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.